Biomerica (BMRA)

Executive Summary

Biomerica is a global biomedical technology company focused on developing, patenting, and manufacturing advanced diagnostic and therapeutic products, primarily targeting gastrointestinal and inflammatory diseases. Founded in 1971 and headquartered in Irvine, California, the company is publicly traded under the ticker BMRA. Biomerica's product portfolio aims to improve patient health outcomes while reducing overall healthcare costs. With a market valuation of approximately $6.7 million (estimated), the company appears to be a micro-cap with limited revenue visibility. Its core research and development is centered on diagnostics for conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), areas with significant unmet clinical need. However, the company has not disclosed any recent FDA approvals or commercial product launches, and its publication count is zero, suggesting early-stage development or a lack of recent milestones. The small market cap and low profile indicate high risk, but potential upside exists if the company can advance its pipeline toward commercialization.

Upcoming Catalysts (preview)

• TBDFDA Clearance or Approval of Lead Diagnostic Product40% success
• TBDStrategic Partnership or Licensing Agreement30% success
• TBDPublication of Clinical Trial Data for GI/Inflammatory Disease Test25% success